UCLH CANCER STRATEGY July 2015 Geoff Bellingan Medical Director, - - PowerPoint PPT Presentation

▶
uclh
SMART_READER_LITE
LIVE PREVIEW

UCLH CANCER STRATEGY July 2015 Geoff Bellingan Medical Director, - - PowerPoint PPT Presentation

Dec 20, 2022 222 likes •707 views

UCLH CANCER STRATEGY July 2015 Geoff Bellingan Medical Director, Surgery & Cancer, UCLH Kirit Ardeshna Divisional Clinical Director, UCLH Cancer Tariq Enver Director, UCL Cancer Institute Kathy Pritchard Jones CMO, London

slide-1
SLIDE 1

UCLH CANCER STRATEGY

July 2015

Geoff Bellingan – Medical Director, Surgery & Cancer, UCLH Kirit Ardeshna – Divisional Clinical Director, UCLH Cancer Tariq Enver – Director, UCL Cancer Institute Kathy Pritchard Jones – CMO, London Cancer Nick Kirby – Divisional Manager, UCLH Cancer

slide-2
SLIDE 2

SPECIALIST CANCER EXPANSION

1,557 1,231 500 1,000 1,500 2,000 2014/15 2010/11 Radiotherap… 1,495 915 500 1,000 1,500 2,000 2014/15 2010/11 Chemotherapy… 1,300 800 200 400 600 800 1,000 1,200 1,400 2014/15 2010/11

Cancer…

27,469 14,593 10,000 20,000 30,000 2014/15 2010/11 Cancer… 3,404 2,759 1,000 2,000 3,000 4,000 2014/15 2010/11 Cancer… $119,000,000 £78,000,000 $0 $50,000,000 $100,000,000 $150,000,000 2014/15 2010/11

Cancer Division Income

27% 63% 63% 23% 88% 51%

New Radiotherapy Patients Chemotherapy Cycles Cancer Surgery Cancer Daycases Cancer Inpatients Cancer Division Income

slide-3
SLIDE 3

UCH CANCER

Franchised Models of Care Integrated Cancer Diagnostics Centre for Cancer Precision Medicine London Cancer School of Cancer Education Centre for Cancer Outcomes

slide-4
SLIDE 4

Basic research Clinical trials Supra regional referrals Service innovators

Skin Breast Gynae Neuro-onc GI Head & Neck Haem-onc Lung CTYA Sarcoma Uro-onc

slide-5
SLIDE 5

Basic research Clinical trials Supra regional referrals Service innovators

Skin Breast Gynae Neuro-onc GI Head & Neck Haem-onc Lung CTYA Sarcoma Uro-onc

slide-6
SLIDE 6

Basic research Clinical trials Supra regional referrals Service innovators

Skin Breast Gynae Neuro-onc GI Head & Neck Haem-onc Lung CTYA Sarcoma Uro-onc

slide-7
SLIDE 7

Basic research Clinical trials Supra regional referrals Service innovators

Skin Breast Gynae Neuro-onc GI Head & Neck Haem-onc Lung CTYA Sarcoma Uro-onc

slide-8
SLIDE 8

Basic research Clinical trials Supra regional referrals Service innovators

Skin Breast Gynae Neuro-onc GI Head & Neck Haem-onc Lung CTYA Sarcoma Uro-onc

slide-9
SLIDE 9

Basic research Clinical trials Supra regional referrals Service innovators

Skin Breast Gynae Neuro-onc GI Head & Neck Haem-onc Lung CTYA Sarcoma Uro-onc

slide-10
SLIDE 10

Basic research Clinical trials Supra regional referrals Service innovators

Skin Breast Gynae Neuro-onc GI Head & Neck Haem-onc Lung CTYA Sarcoma Uro-onc

slide-11
SLIDE 11

Basic research Clinical trials Supra regional referrals Service innovators

Skin Breast Gynae Neuro-onc GI Head & Neck Haem-onc Lung CTYA Sarcoma Uro-onc

slide-12
SLIDE 12

Endoscopy Imaging & Interventional Radiology Radiotherapy Chemotherapy Pathology Basic research Clinical trials Supra regional referrals Service innovators

slide-13
SLIDE 13

Endoscopy Imaging & Interventional Radiology Radiotherapy Chemotherapy Pathology Basic research Clinical trials Supra regional referrals Service innovators

slide-14
SLIDE 14

Endoscopy Imaging & Interventional Radiology Radiotherapy Chemotherapy Pathology Basic research Clinical trials Supra regional referrals Service innovators

slide-15
SLIDE 15
slide-16
SLIDE 16

25 en-suite rooms

slide-17
SLIDE 17

25 en-suite rooms 65 cases UCH plus 55 from BH

slide-18
SLIDE 18

25 en-suite rooms 65 cases UCH plus 55 from BH 400 cases UCH plus 125 BHRUT

slide-19
SLIDE 19

25 en-suite rooms 65 cases UCH plus 55 from BH 400 cases UCH plus 125 BHRUT 200 cases UCH plus 240 BH

slide-20
SLIDE 20

25 en-suite rooms 65 cases UCH plus 55 from BH 400 cases UCH plus 125 BHRUT 200 cases UCH plus 240 BH 420 cases QS plus 100 BH

slide-21
SLIDE 21
slide-22
SLIDE 22

M T W T F M T W T F AM PM Current Future

slide-23
SLIDE 23

M T W T F M T W T F AM PM Current Future

slide-24
SLIDE 24
slide-25
SLIDE 25

UCL Cancer Institute

Our mission is to decrease the burden of cancer through laboratory and clinical research; develop excellence and place UCL as a major national and international hub for cancer research; and educate the next generation of cancer researchers and clinicians.

UCL CANCER INSTITUTE

slide-26
SLIDE 26

UCL Cancer Institute

Precision Cancer Medicine

The future of treatment for patients is precision cancer medicine – a treatment package that is specific to the individual’s

  • wn unique cancer.
  • It is our vision that, within five years, every patient

will have their own personalised cancer pathway, -- early diagnosis and screening, imaging or biopsy, genomic analysis of their cancer, state-of-the- art clinical trials.

slide-27
SLIDE 27

UCL Cancer Institute

IMMUNOTHERAPY

Syncona 30m CAR T, IIT@RF, CRUK Accelerator 5m, BMS IO Network, Senior (BRC) and Junior (Fellowship) Recruitment Wellcome Strategic Award and National Centre Status

slide-28
SLIDE 28

UCL Cancer Institute

MOLECULAR PATHOLOGY

UCL-AD Gene panels, UCL- AD Immuno, Digital Pathology, MRC Single Cell Facility 3m, E Med Lab 15m Fragmented, Sector wide Solution, 0.25 UCL FTE

slide-29
SLIDE 29

UCL Cancer Institute

TUMOUR HETEROGENEITY

Personalised Med, Cancer evolution, Cancer Biology, CRICK, UCL Evolution

slide-30
SLIDE 30

UCL Cancer Institute

ENERGY and IMAGING

Proton Beam Chair, CRUK Cancer Imaging Centre, CABI, BRC Imaging Theme, Charles Bell House Image Directed Therapy, MRC Theranostic Platform 6m, BEAMS

slide-31
SLIDE 31

UCL Cancer Institute

CLINICAL TRIALS PHASE 1

CRUK CTC, ECMC, Sarah Canon JV New Phase 1 lead

slide-32
SLIDE 32

Slide 32

London Cancer - the integrated cancer system for a population of >3.2 million in north central & east London and west Essex

Operational since April 2012 (assured in August 2011) 11 provider trusts Co-developed with patients and primary care

slide-33
SLIDE 33

Cancer is a “burning platform” for the NHS

  • 10 years after a national cancer plan and

cancer networks, UK still has ~10% worse survival than W Europe - only catching up in breast.

  • Cancer will affect 1 in 2 of those born after

1960

  • Cancer is the biggest killer at all ages -

130,000 deaths/yr.

  • Number of people living with and beyond

cancer will increase from 2.5million in 2015 to 3.4 million in 2030.

  • 70% of cancer patients have 1 or more Long

Term Conditions, 29% have 3 or more

slide-34
SLIDE 34

Up to 10% difference in 1 year survival by CCG

slide-35
SLIDE 35

Lung Cancer: almost 2-fold variation in 1 yr survival by provider and improvement over time

%

slide-36
SLIDE 36

Large variations in surgical practice across London Cancer

slide-37
SLIDE 37

Cancer Patient Experience

Cancer Patient Experience Survey 2014

  • UCLH position has

improved and is now

  • utside the lowest 20

trusts; feedback far from indicating a world class experience.

  • London Cancer is the

poorest performing network of providers in England; 6 of the bottom 10 providers are from London Cancer.

  • There is a collective

responsibility to respond to this feedback as a network.

slide-38
SLIDE 38

Slide 38

  • Save 200-400 lives a year
  • Improve 1 year cancer survival rates
  • Improve cancer patient experience
  • Increase access to innovation/trials

We will

  • Improving early access to diagnostics
  • Connecting the cancer system further
  • Standardising & franchising cancer services
  • Creating a Cancer Outcomes Unit to drive world class standards &

global visibility

By

Our Vanguard ambition is for better smoother quality cancer care supporting self management & local care

slide-39
SLIDE 39

Slide 39

UCH CANCER

Franchised Models of Care Integrated Cancer Diagnostics Centre for Cancer Precision Medicine London Cancer School of Cancer Education Centre for Cancer Outcomes

DRIVERS OF STRATEGIC CHANGE

Six new programmes of work will provide focus and drive for many of the strategic objectives. Together these are essential in realising the ambition to be the best Cancer Centre in Europe.

slide-40
SLIDE 40

Slide 40

UCH CANCER

Franchised Models of Care Integrated Cancer Diagnostics Centre for Cancer Precision Medicine London Cancer School of Cancer Education Centre for Cancer Outcomes

slide-41
SLIDE 41

Slide 41

UCH CANCER Franchised Models of Care Integrated Cancer Diagnostics Centre for Cancer Precision Medicine London Cancer School of Cancer Education Centre for Cancer Outcomes

Centre for Cancer Outcomes

  • Analyse & Interpret
  • Outcomes books
  • Research & Population

Health

  • Commissioning & Policy
  • New measures

School of Cancer Education

  • Patient Pathways &

Experience

  • Clinical Trials
  • Professional Programmes

London Cancer

  • Tumour Pathways Boards
  • Define best practice
  • Sector ICT
slide-42
SLIDE 42

Slide 42

UCH CANCER

Franchised Models of Care Integrated Cancer Diagnostics Centre for Cancer Precision Medicine London Cancer School of Cancer Education Centre for Cancer Outcomes

slide-43
SLIDE 43

Slide 43

UCH CANCER Franchised Models of Care Integrated Cancer Diagnostics Centre for Cancer Precision Medicine London Cancer School of Cancer Education Centre for Cancer Outcomes

Centre for Cancer Precision Medicine

  • Early Phase and SCRI
  • Immunotherapy
  • Radiation Therapy
  • Personalised Medicine
  • Genomics

Franchised Models of Care

  • Chemotherapy &

Radiotherapy

  • Organisational form to enable

patient and financial benefits

  • Philosophy of care closer to

home

Integrated Cancer Diagnostics

  • Implement what we know
  • Identify need by tumour and

diagnostic modality

  • Innovate in models of

delivery

slide-44
SLIDE 44

Slide 44

SYSTEM LEADERSHIP

Define pathways & standards Pioneering new models of care Lead world class research Inform commissioning & policy Deliver Cancer Education & Training Reimbursement for service delivery

Performance management against access

Procurement and tendering for service provision Coordinate service improvement Provide highly specialist cancer care

COMMISSIONING

Cancer Outcomes Unit Cancer ICT strategy & enablers

slide-45
SLIDE 45

Slide 45

A Cancer Campus at UCL

Cancer Institute UCLH NIHR CRF UCH Macmillan Cancer Centre Sarah Cannon Research Institute Phase 4 Proton Beam (160 beds) Phase 5 Cancer Institute 2

ENABLERS - Estates & Infrastructure

slide-46
SLIDE 46

STAFF & PATIENT Cancer Services UCLH Sector Providers Government & Commissioners Private & Charitable Public School of Cancer

slide-47
SLIDE 47

ENGAGEMENT

CONTRIBUTORS

UCLH CANCER Internal External

MDT lead meetings CNS Community of Practice GP Vanguard workshops Patient Vanguard workshops London Cancer Operational Leads meeting UCH-Macmillan Partnership Board R&D Strategy Workshop Patient Experience Strategy Workshop Outcomes Strategy Workshop Workforce Strategy Workshop Radiology Consultant meeting Pathology Leads meeting Imaging leads meeting Cancer Strategy Staff Survey CCTU away day Cancer Pharmacy team meeting MSIS team meeting Cancer Senior Staff meetings Radiotherapy Physics team meeting CCSG Islington and Camden GP Cancer Leads Visit to Christie Cancer Outcomes Unit Surgery & Cancer Board Commissioner Workshop Vanguard engagement with all London Cancer hospitals Vanguard engagement with all London Cancer CCGs UCLPartners Vanguard engagement London Cancer Vanguard engagement CRUK & Macmillan Vanguard engagement